NASH Cirrhosis: A Systematic Review of Phase 2B Trials

Bipneet Singh^1*, Sruthi Ramanan¹, Waryaam Singh², Gurleen Kaur³, Palak Grover¹, Nidhishri Sridhar⁴

¹Internal Medicine, Henry Ford, Jackson, USA.
²Department of Nephrology and Hypertension, Mayo Clinic, Rochester, USA.
³Internal Medicine, GMC Amritsar, Amritsar, India.
⁴Internal Medicine, Vydehi Institute of Medical Sciences and Research Centre, Bangalore, India.

DOI: 10.4236/ojgas.2025.154014                

Abstract

Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver disease in the United States. It includes a spectrum of conditions, from simple steatosis to more severe forms such as nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Recently, NAFLD has been redefined as metabolic dysfunction-associated fatty liver disease (MAFLD) to better reflect its association with metabolic dysregulation. Moreover, people with MAFLD can have a component of alcohol use, making MAFLD and alcoholic liver disease, 2 ends of a spectrum. It also moves away from the stigma of terminology previously used. This summary reviews the findings from recent phase 2b clinical trials that assess the efficacy and safety of various drugs targeting NAFLD and NASH. A systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The literature search included databases like PubMed, Embase, Cochrane Library, and Google Scholar, focusing on studies published within the last five years. Eleven randomized controlled trials (RCTs) met the inclusion criteria. For PPAR Agonists, the EMMINENCE trial evaluated a PPAR agonist, but did not meet its primary endpoints. In contrast, the NATIVE trial assessed lanifibranor and found significant improvements. FGF-21 and FGF-19 analogs were investigated in several trials with mixed results. The Harmony trial on efruxifermin (an FGF21 analog) reported significant improvements in fibrosis, highlighting its potential in treating NASH. However, the Alpine 2/3 and Alpine 4 trials on aldafermin (an FGF19 analog) did not demonstrate significant efficacy in fibrosis reduction. These mixed outcomes suggest that while FGF-based therapies hold promise, their effectiveness needs further research. Belapectin, a galectin-3 inhibitor, did not show significant benefits. TANDEM trial assessed the combination of tropifexor (TXR) and cenicriviroc (CVC), showing safety and tolerability with notable reductions in liver enzyme levels (ALT, AST, GGT). FXR agonists like tropifexor modulate bile acid metabolism and inflammatory pathways, while CCR inhibitors like cenicriviroc target chemokine receptors involved in hepatic inflammation and fibrosis. The combination therapy approach may offer synergistic benefits in managing NASH. The reviewed trials underscore the complexity of NAFLD and NASH treatment, with multiple therapeutic targets. PPAR agonists like lanifibranor show promise, particularly in resolving NASH. The variability in the efficacy of FGF-based therapies highlights the need for further research to identify the most effective agents and patient profiles.

Keywords

PPAR, Icona, Tandem, Harmony, Falcon

Conflicts of Interest

The authors declare no conflicts of interest regarding the publication of this paper.

References

[1]	Castera, L., Friedrich-Rust, M. and Loomba, R. (2019) Noninvasive Assessment of Liver Disease in Patients with Nonalcoholic Fatty Liver Disease. Gastroenterology, 156, 1264-1281.e4. https://doi.org/10.1053/j.gastro.2018.12.036
[2]	Eslam, M. and George, J. (2020) Reply to: Correspondence Regarding “A New Definition for Metabolic Dysfunction-Associated Fatty Liver Disease: An International Expert Consensus Statement”. Journal of Hepatology, 73, Article 1575. https://doi.org/10.1016/j.jhep.2020.07.045
[3]	Targher, G., Byrne, C.D., Lonardo, A., Zoppini, G. and Barbui, C. (2016) Non-Alcoholic Fatty Liver Disease and Risk of Incident Cardiovascular Disease: A Meta-Analysis. Journal of Hepatology, 65, 589-600. https://doi.org/10.1016/j.jhep.2016.05.013
[4]	Kleiner, D.E., Brunt, E.M., Van Natta, M., Behling, C., Contos, M.J., Cummings, O.W., et al. (2005) Design and Validation of a Histological Scoring System for Nonalcoholic Fatty Liver Disease. Hepatology, 41, 1313-1321. https://doi.org/10.1002/hep.20701
[5]	Omokaro, S.O. and Golden, J.K. (2020) The Regulatory State of Nonalcoholic Steatohepatitis and Metabolism. Endocrinology, Diabetes & Metabolism, 3, e00113. https://doi.org/10.1002/edm2.113
[6]	Fon Tacer, K., Bookout, A.L., Ding, X., Kurosu, H., John, G.B., Wang, L., et al. (2010) Research Resource: Comprehensive Expression Atlas of the Fibroblast Growth Factor System in Adult Mouse. Molecular Endocrinology, 24, 2050-2064. https://doi.org/10.1210/me.2010-0142
[7]	Sanderson, L.M., Kersten, S., Bunce, C.M. and Campbell, M.J. (2010) Receptors, Nuclear and Concepts, Current and Dordrecht, Future Challenges. Springer.
[8]	Gawrieh, S., Noureddin, M., Loo, N., Mohseni, R., Awasty, V., Cusi, K., et al. (2021) Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial. Hepatology, 74, 1809-1824. https://doi.org/10.1002/hep.31843
[9]	Fraile, J.M., Palliyil, S., Barelle, C.J., Porter, A.J. and Kovaleva, M. (2021) Non-Alcoholic Steatohepatitis (NASH)—A Review of a Crowded Clinical Landscape, Driven by a Complex Disease. Drug Design, Development and Therapy, 15, 3997-4009. https://doi.org/10.2147/dddt.s315724
[10]	Page, M.J., McKenzie, J.E., Bossuyt, P.M., et al. (2021) The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. BMJ, 372, n71.
[11]	Cumpston, M., Li, T., Page, M.J., Chandler, J., Welch, V.A., Higgins, J.P., et al. (2019) Updated Guidance for Trusted Systematic Reviews: A New Edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database of Systematic Reviews, No. 10, Article No. ED000142. https://doi.org/10.1002/14651858.ed000142
[12]	Higgins, J.P.T., Altman, D.G., Gotzsche, P.C., Juni, P., Moher, D., Oxman, A.D., et al. (2011) The Cochrane Collaboration’s Tool for Assessing Risk of Bias in Randomised Trials. BMJ, 343, d5928. https://doi.org/10.1136/bmj.d5928
[13]	Harrison, S.A., Alkhouri, N., Davison, B.A., Sanyal, A., Edwards, C., Colca, J.R., et al. (2020) Insulin Sensitizer MSDC-0602K in Non-Alcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study. Journal of Hepatology, 72, 613-626. https://doi.org/10.1016/j.jhep.2019.10.023
[14]	Chalasani, N., Abdelmalek, M.F., Garcia-Tsao, G., Vuppalanchi, R., Alkhouri, N., Rinella, M., et al. (2020) Effects of Belapectin, an Inhibitor of Galectin-3, in Patients with Nonalcoholic Steatohepatitis with Cirrhosis and Portal Hypertension. Gastroenterology, 158, 1334-1345.e5. https://doi.org/10.1053/j.gastro.2019.11.296
[15]	Francque, S.M., Bedossa, P., Ratziu, V., Anstee, Q.M., Bugianesi, E., Sanyal, A.J., et al. (2021) A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. New England Journal of Medicine, 385, 1547-1558. https://doi.org/10.1056/nejmoa2036205
[16]	Harrison, S.A., Frias, J.P., Neff, G., Abrams, G.A., Lucas, K.J., Sanchez, W., et al. (2023) Safety and Efficacy of Once-Weekly Efruxifermin versus Placebo in Non-Alcoholic Steatohepatitis (HARMONY): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 2b Trial. The Lancet Gastroenterology & Hepatology, 8, 1080-1093. https://doi.org/10.1016/s2468-1253(23)00272-8
[17]	Fraser, D.A., Harrison, S.A. and Schuppan, D. (2022) Icosabutate: Targeting Metabolic and Inflammatory Pathways for the Treatment of Nash. Expert Opinion on Investigational Drugs, 31, 1269-1278. https://doi.org/10.1080/13543784.2022.2159804
[18]	Pedrosa, M., Seyedkazemi, S., Francque, S., Sanyal, A., Rinella, M., Charlton, M., et al. (2020) A Randomized, Double-Blind, Multicenter, Phase 2b Study to Evaluate the Safety and Efficacy of a Combination of Tropifexor and Cenicriviroc in Patients with Nonalcoholic Steatohepatitis and Liver Fibrosis: Study Design of the TANDEM Trial. Contemporary Clinical Trials, 88, Article 105889. https://doi.org/10.1016/j.cct.2019.105889
[19]	Harrison, S.A., Abdelmalek, M.F., Neff, G., Gunn, N., Guy, C.D., Alkhouri, N., et al. (2022) Aldafermin in Patients with Non-Alcoholic Steatohepatitis (ALPINE 2/3): A Randomised, Double-Blind, Placebo-Controlled, Phase 2b Trial. The Lancet Gastroenterology & Hepatology, 7, 603-616. https://doi.org/10.1016/s2468-1253(22)00017-6
[20]	Rinella, M.E., Lieu, H.D., Kowdley, K.V., Goodman, Z.D., Alkhouri, N., Lawitz, E., et al. (2024) A Randomized, Double-Blind, Placebo-Controlled Trial of Aldafermin in Patients with NASH and Compensated Cirrhosis. Hepatology, 79, 674-689. https://doi.org/10.1097/hep.0000000000000607
[21]	Brown, E.A., Minnich, A., Sanyal, A.J., Loomba, R., Du, S., Schwarz, J., et al. (2023) Effect of Pegbelfermin on NASH and Fibrosis-Related Biomarkers and Correlation with Histological Response in the FALCON 1 Trial. JHEP Reports, 5, Article 100661. https://doi.org/10.1016/j.jhepr.2022.100661
[22]	Abdelmalek, M.F., Sanyal, A.J., Nakajima, A., Neuschwander-Tetri, B.A., Goodman, Z.D., Lawitz, E.J., et al. (2024) Pegbelfermin in Patients with Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study. Clinical Gastroenterology and Hepatology, 22, 113-123.e9. https://doi.org/10.1016/j.cgh.2023.04.012
[23]	Loomba, R., Sanyal, A.J., Kowdley, K.V., Bhatt, D.L., Alkhouri, N., Frias, J.P., et al. (2023) Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in Nash. New England Journal of Medicine, 389, 998-1008. https://doi.org/10.1056/nejmoa2304286
[24]	Liss, K.H.H. and Finck, B.N. (2017) PPARs and Nonalcoholic Fatty Liver Disease. Biochimie, 136, 65-74. https://doi.org/10.1016/j.biochi.2016.11.009
[25]	Ocker, M. (2020) Fibroblast Growth Factor Signaling in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Paving the Way to Hepatocellular Carcinoma. World Journal of Gastroenterology, 26, 279-290. https://doi.org/10.3748/wjg.v26.i3.279
[26]	Kojima, S., Watanabe, N., Numata, M., Ogawa, T. and Matsuzaki, S. (2003) Increase in the Prevalence of Fatty Liver in Japan over the Past 12 Years: Analysis of Clinical Background. Journal of Gastroenterology, 38, 954-961. https://doi.org/10.1007/s00535-003-1178-8
[27]	Zhou, Y. (2007) Prevalence of Fatty Liver Disease and Its Risk Factors in the Population of South China. World Journal of Gastroenterology, 13, 6419-6424. https://doi.org/10.3748/wjg.v13.i47.6419
[28]	Tamaki, N., Munaganuru, N., Jung, J., Yonan, A.Q., Bettencourt, R., Ajmera, V., et al. (2021) Clinical Utility of Change in Nonalcoholic Fatty Liver Disease Activity Score and Change in Fibrosis in NAFLD. Clinical Gastroenterology and Hepatology, 19, 2673-2674.e3. https://doi.org/10.1016/j.cgh.2020.11.005
[29]	Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L. and Wymer, M. (2016) Global Epidemiology of Nonalcoholic Fatty Liver Disease—Meta‐Analytic Assessment of Prevalence, Incidence, and Outcomes. Hepatology, 64, 73-84. https://doi.org/10.1002/hep.28431
[30]	Brunt, E.M. (2017) Nonalcoholic Fatty Liver Disease and the Ongoing Role of Liver Biopsy Evaluation. Hepatology Communications, 1, 370-378. https://doi.org/10.1002/hep4.1055
[31]	Mak, I.W., Evaniew, N., Ghert, M. (2014) Lost in Translation: Animal Models and Clinical Trials in Cancer Treatment. American Journal of Translational Research, 6, 114-118.
[32]	Nishimura, T., Utsunomiya, Y., Hoshikawa, M., Ohuchi, H. and Itoh, N. (1999) Structure and Expression of a Novel Human FGF, FGF-19, Expressed in the Fetal Brain. Biochimica et Biophysica Acta (BBA)—Gene Structure and Expression, 1444, 148-151. https://doi.org/10.1016/s0167-4781(98)00255-3
[33]	Markan, K.R., Naber, M.C., Ameka, M.K., Anderegg, M.D., Mangelsdorf, D.J., Kliewer, S.A., et al. (2014) Circulating FGF21 Is Liver Derived and Enhances Glucose Uptake during Refeeding and Overfeeding. Diabetes, 63, 4057-4063. https://doi.org/10.2337/db14-0595
[34]	Nishimura, T., Nakatake, Y., Konishi, M. and Itoh, N. (2000) Identification of a Novel FGF, FGF-21, Preferentially Expressed in the Liver. Biochimica et Biophysica Acta (BBA)—Gene Structure and Expression, 1492, 203-206. https://doi.org/10.1016/s0167-4781(00)00067-1
[35]	Micanovic, R., Raches, D.W., Dunbar, J.D., Driver, D.A., Bina, H.A., Dickinson, C.D., et al. (2008) Different Roles of N‐ and C‐ Termini in the Functional Activity of FGF21. Journal of Cellular Physiology, 219, 227-234. https://doi.org/10.1002/jcp.21675
[36]	Wu, X., Ge, H., Gupte, J., Weiszmann, J., Shimamoto, G., Stevens, J., et al. (2007) Co-receptor Requirements for Fibroblast Growth Factor-19 Signaling. Journal of Biological Chemistry, 282, 29069-29072. https://doi.org/10.1074/jbc.c700130200